高级检索
吴雯, 周贵香, 施超, 高雨蒙, 彭红红, 陆兵. 新型冠状病毒感染者特异性抗体变化特征分析[J]. 中国公共卫生, 2022, 38(6): 804-807. DOI: 10.11847/zgggws1136686
引用本文: 吴雯, 周贵香, 施超, 高雨蒙, 彭红红, 陆兵. 新型冠状病毒感染者特异性抗体变化特征分析[J]. 中国公共卫生, 2022, 38(6): 804-807. DOI: 10.11847/zgggws1136686
WU Wen, ZHOU Gui-xiang, SHI Chao, . Temporal profile of specific antibody against SARS-CoV-2 among infected people: a literature study[J]. Chinese Journal of Public Health, 2022, 38(6): 804-807. DOI: 10.11847/zgggws1136686
Citation: WU Wen, ZHOU Gui-xiang, SHI Chao, . Temporal profile of specific antibody against SARS-CoV-2 among infected people: a literature study[J]. Chinese Journal of Public Health, 2022, 38(6): 804-807. DOI: 10.11847/zgggws1136686

新型冠状病毒感染者特异性抗体变化特征分析

Temporal profile of specific antibody against SARS-CoV-2 among infected people: a literature study

  • 摘要:
      目的  为了客观的描述新型冠状病毒感染者抗体出现及变化规律。
      方法  检索PubMed、中国知网、万方数据库中公开发表的所有文章。限定搜索词,检索时间限定为2021年7月前。采用Excle 2016、SPSS 25.0收集汇总分析。
      结果  感染者的IgM、IgG、IgA和中和抗体的中位出现时间分别为出现症状后的第8 d(第1~28 d)、第10 d(第0~29 d),第7 d(第1~13 d),第9 d(第1~25.5 d);IgM、IgG、IgA和中和抗体的中位高峰时间为出现症状后的第16.5 d(第10~30 d)、第21 d(第15~30 d)、第21 d(第15~30 d)、第24 d(第10~45 d);IgM、IgG、IgA和中和抗体的中位持续时间为出现症状后的63 d(60~84 d)、105 d(42~365 d)、 41 d(30~100 d)、101 d(65~270 d)。
      结论  SARS-CoV-2感染者体内IgA出现的最早,持续时间也最短;IgG出现的最晚,持续时间也最长;IgM最先达到峰值,中和抗体最晚达到峰值。与SARS-CoV确诊患者相比,SARS-CoV-2确诊患者的IgM持续时间较短;同时,SARS-CoV-2确诊患者的IgG和中和抗体的持续时间也要短于SARS-CoV和MERS确诊患者。

     

    Abstract:
      Objective  To describe the occurrence and dynamic changes of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in infected people.
      Methods  Relevant studies published up to July 2021 were retrieved through systematically searching on PubMed, China National Knowledge Infrastructure (CNKI), and Wanfang Database. Excle 2016 and SPSS 25.0 were used in data collection and analysis.
      Results  From the onset of coronavirus disease 2019 (COVID-19) symptoms, the median time of seroconversion was 8 days (the minimum – the maximum: 1 – 28 days) for immunoglobulin M (IgM), 10 days (0 – 29 days) for IgG, 7 days (1 – 13 days) for IgA, and 9 days (1 – 25.5 days) for neutralizing antibody; the median time of peak antibody titer was 16.5 days (10 – 30 days) for IgM, 21 days (15 – 30 days) for IgG, 21 days (15 – 30 days) for IgA, and 24 days (10 – 45 days) for neutralizing antibody; and the median persistent time of antibody was 63 days (60 – 84 days) for IgM, 105 days (42 – 365 days) for IgG, 41 days (30 – 100 days) for IgA, and 101 days (65 – 270 days) for neutralizing antibody, respectively.
      Conclusion  Among seroconversions of specific antibodies against SARS-CoV-2 in infected persons, IgA occurred first but with the shortest persistent duration, while IgG occurred latest but with the longest persistent duration; the serum titer of IgM peaked first, but that of neutralizing antibody the latest. The duration of serum IgM positive of patients with SARS-CoV-2 infection was shorter than that of patients with SARS-CoV infection. Meanwhile, the durations of serum positive for IgG and neutralizing antibody in SARS-CoV-2 infected patients were shorter than those in the patients with SARS-CoV or Middle East respiratory syndrome coronavirus (MERS-CoV) infection.

     

/

返回文章
返回